FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects

The U.S. Food and Drug Administration approved Merck & Co.’s Keytruda drug to treat tumors with a certain genetic defect—the first time the agency has cleared a cancer drug for a use not tied to the site of a tumor.

from WSJ.com: US Business http://ift.tt/2rxRkXi
via IFTTT